Biotech entity
All 1 tracked stories fall under one category: pharma. GSBR-1290 is most often covered alongside B Group, Inc., which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention GSBR-1290, all published on March 23, 2026.
Last mentioned: Mar 23, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. GSBR-1290 is most often covered alongside B Group, Inc., which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention GSBR-1290, all published on March 23, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 11 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering GSBR-1290. Shared-story counts are live from our verified record — not editorial picks.
Structure Therapeutics (GPCR) has faced a 28% year-to-date decline in 2026, even as institutional investor B Group, Inc. disclosed a new $6.26 million position. The clinical-stage biotech remains a high-stakes player in the competitive oral GLP-1 market with its lead candidate, GSBR-1290.
GSBR-1290 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
